The impact of the mode of adjuvant therapy on intermediate-risk and high-risk uterine endometrial cancer: A retrospective multicenter study
Not Applicable
Recruiting
- Conditions
- Endometrial cancer
- Registration Number
- JPRN-UMIN000016005
- Lead Sponsor
- KCOG and Endometrial Cancer Program of Fudan University Shanghai Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with incomplete clinicopathological data. Patients with more thean 1 primary tumor.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie adjuvant therapy efficacy in intermediate-risk endometrial cancer?
How does adjuvant radiation compare to chemotherapy in high-risk endometrial cancer recurrence prevention?
Which biomarkers are associated with improved outcomes in endometrial cancer adjuvant treatment selection?
What adverse events are commonly reported in adjuvant therapies for endometrial cancer and how are they managed?
Are there combination approaches or targeted therapies being explored alongside traditional adjuvant treatments for endometrial cancer?